Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CB-5083 in Advanced Solid Tumors
NCT02243917Phase 1Terminated
- Sponsor
- Cleave Therapeutics
- Start
- Oct 2014
- Primary completion
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of CB-5083 in solid tumor, colorectal cancer (CRC), renal cell carcinoma (RCC) and 1 more (3 arms), sponsored by Cleave Therapeutics. Primary endpoints: Dose Limiting Toxicities at 28 days, Pharmacokinetic Profile and 2 more. Started Oct 2014; status: terminated.
02
Drugs
CB-5083
03
Conditions
solid tumorcolorectal cancer (CRC)renal cell carcinoma (RCC)Pancreatic neuroendocrine tumor (PanNET)
Beyond the preview
Go deeper on NCT02243917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02243917.